Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSCD101
- Development stage
- Phase 1
- Lead developer
- CliPS
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
LSCD101 is an autologous cell therapy consisting of a cultured limbal epithelial cell sheet developed by G.CLIPS biotech. It is designed for the treatment of intractable limbal stem cell deficiency (LSCD), a condition where the loss of stem cells at the edge of the cornea leads to corneal opacity and vision loss. The therapy involves harvesting a small biopsy of healthy limbal tissue from the patient's own eye, expanding the limbal stem cells in vitro to form a cohesive epithelial sheet, and then transplanting this sheet onto the damaged cornea to regenerate the ocular surface and restore visual function.
- Other names
- Cultured Autologous Limbal Epithelial Cell Sheet
Beyond the preview
Go deeper on LSCD101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSCD101.